The following is a sample from a larger document.
This section is for: What is Established
The section is from a Focused Issue Brief on: Assessing Scientific Causation Claims in PFAS Exposure Litigation
The primary research jurisdiction is: United States of America
Section 3: What is Established
The physical properties and basic behavior of PFAS compounds in environmental and biological systems rest on decades of consistent measurement and observation. Per- and polyfluoroalkyl substances are synthetic chemicals characterized by carbon-fluorine bonds, which represent the strongest single bond in organic chemistry. This fundamental chemical property drives their environmental persistence and biological accumulation. The carbon-fluorine bond requires more energy to break than biological or environmental processes typically provide.
PFAS compounds are generally considered anthropogenic and are not known to occur naturally at environmentally relevant levels. Detections in environmental samples, human blood, or tissue are understood to reflect synthetic origin. Manufacturing began in the 1940s, with large-scale production and use expanding through the 1970s and continuing today.
The two most extensively studied PFAS are perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS). Companies produced these in the highest volumes and they have the longest exposure history in human populations.
These compounds accumulate in human blood serum with elimination half-lives measured in years. For PFOA, the serum elimination half-life ranges from 2.3 to 4.4 years across multiple studies. For PFOS, the range extends to 5.4 years. After exposure stops, blood levels decline slowly, with half the compound remaining in blood serum after several years. Even shorter-chain PFAS are measured in weeks to months rather than hours.
PFAS migrate through groundwater and surface water systems with minimal degradation under typical environmental conditions. They resist the typical environmental processes like bacterial action, sunlight exposure, or chemical oxidation that neutralize most organic pollutants. Once released to the environment, they remain largely intact and mobile. This persistence contributes to their detection in drinking water supplies far from known sources and in remote regions such as the Arctic and deep ocean waters.
The compounds cross biological membranes and distribute throughout the body. They bind to serum albumin in blood, accumulate in liver and kidney tissues, and cross the placental barrier during pregnancy. PFOA and PFOS appear in umbilical cord blood at concentrations averaging 70-80% of maternal blood levels, documenting in-utero exposure. They also transfer through breast milk at lower concentrations.
Background exposure is widespread in developed countries.
The CDC’s National Health and Nutrition Examination Survey has detected PFOA and PFOS in over 95% of participants since monitoring began in 1999. This finding reflects widespread environmental contamination and the persistence of compounds released over decades of use. Blood levels in the general population have declined since voluntary phase-outs of PFOA and PFOS manufacturing in the United States, but remain detectable years later.
Occupational exposures in manufacturing facilities have produced blood levels substantially higher than background population levels, in some documented settings reaching 10 to 100 times higher. The highest documented exposures occurred in workers at DuPont’s Parkersburg, West Virginia facility and 3M’s Cottage Grove, Minnesota facility. These worker populations, along with nearby communities exposed through environmental contamination, provide the primary epidemiological data on health effects at elevated exposure levels.
Animal studies demonstrate consistent dose-response relationships. In laboratory rats and mice, PFOA exposure produces liver effects including hepatocellular hypertrophy and increased liver weight at doses above 1 milligram per kilogram of body weight per day. PFOS produces similar liver effects along with decreased body weight gain and increased cholesterol levels. These findings have been reported across multiple laboratories, strains, and study designs.
The kidney emerges as a target organ, particularly for PFOA. Chronic exposure produces kidney tumors in male rats at doses of 3 milligrams per kilogram per day and above—adenomas and adenocarcinomas originating in tubular epithelial cells. Similar findings have been reported in multiple long-term bioassays conducted by different research groups.
Developmental effects occur at lower doses than liver or kidney effects. PFOA exposure during pregnancy reduces birth weight and delays development in offspring at maternal doses as low as 1-5 milligrams per kilogram per day, doses that do not produce overt toxicity in the mothers. PFOS exposure produces similar developmental effects at slightly higher doses.
Immune system effects appear across multiple PFAS compounds. Exposure reduces antibody responses to vaccines and increases susceptibility to infectious disease. These effects occur at relatively low doses and involve suppression of T-cell dependent immune responses. The pattern holds for PFOA, PFOS, and several other PFAS compounds.
Human epidemiological studies consistently identify specific health outcomes associated with higher PFAS blood levels. The relationship between PFAS exposure and elevated cholesterol levels appears across multiple study populations for both total cholesterol and LDL cholesterol, with reported effect sizes often showing modest increases in total and LDL cholesterol across exposure gradients.
Higher maternal PFAS blood levels associate with reduced birth weight and increased risk of pregnancy-induced hypertension. The birth weight effect is generally modest in magnitude, with reported reductions in the range of tens of grams across exposure gradients. The hypertension association appears for both pregnancy-induced hypertension and preeclampsia.
Cancer incidence shows specific patterns in highly exposed populations. The C8 Health Project, which studied approximately 69,000 people exposed to PFOA-contaminated drinking water near the DuPont Parkersburg facility, reported elevated incidence of kidney cancer and testicular cancer compared to expected rates. The kidney cancer increase was statistically significant in both men and women. The testicular cancer increase showed a clear dose-response relationship with estimated cumulative PFOA exposure.
Liver enzyme elevations appear consistently in studies of occupationally exposed workers and highly exposed community populations. Alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) levels increase with PFAS blood levels across multiple studies. The increases typically remain within normal clinical ranges but represent consistent elevation above expected levels.
Thyroid hormone disruption occurs in human populations, though the direction varies between PFOA and PFOS. PFOA exposure typically associates with increased thyroid-stimulating hormone (TSH) levels and decreased free thyroxine (T4) levels. PFOS shows more variable associations depending on the population studied.
Kidney function measures show consistent associations with PFAS exposure. Estimated glomerular filtration rate (eGFR) shows inverse associations with higher PFAS blood levels in multiple studies—generally modest but statistically significant across different populations. Chronic kidney disease prevalence also increases with PFAS exposure in several large epidemiological studies.
The regulatory and legal landscape around PFAS has established specific liability pathways and recognition of harm. The EPA has designated PFOA and PFOS as hazardous substances under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), subjecting releases to reporting requirements and potential cleanup liability. Multiple federal agencies including EPA, FDA, and CDC have issued health advisories acknowledging health risks from PFAS exposure at levels found in contaminated communities.
Manufacturing companies have acknowledged significant liability through large settlement agreements. DuPont and its spinoff Chemours agreed to pay $921 million to settle claims related to PFOA contamination from the Parkersburg facility. 3M agreed to pay $10.3 billion to settle drinking water contamination claims from thousands of public water systems. These settlements resolve claims related to alleged contamination and harm, and typically include no admission of legal liability.
Government agencies have issued authoritative assessments concluding that certain PFAS exposures are associated with adverse health effects.
The EPA’s 2022 health advisory for PFOA concluded that lifetime exposure to 0.004 parts per trillion in drinking water may cause adverse health effects. This level approaches current analytical detection limits and reflects EPA’s conclusion that very low lifetime exposures may present health risks. Similar advisories exist for PFOS and other PFAS compounds.
Courts have recognized PFAS contamination as a basis for property damage claims even without proof of actual health effects. Property values have declined in documented instances when PFAS contamination becomes known, even in the absence of diagnosed health effects. Multiple courts have allowed claims for diminished property value, medical monitoring costs, and fear of future disease based solely on documented exposure above background levels.
The persistence and mobility of PFAS compounds create continuing liability for past releases. Unlike many pollutants that degrade or become less mobile over time, certain PFAS remain bioavailable and can continue to migrate through environmental media for decades after release. Contamination from historical manufacturing and disposal practices continues to create new exposures and potential claims years or decades after the original release occurred.
Human biomonitoring data demonstrate that PFAS exposure continues in the present. Blood levels in the general population decline slowly even after major sources are eliminated, reflecting continued exposure from legacy contamination and ongoing releases of other PFAS compounds. This creates a documented pathway from identifiable sources to measurable human exposure for both current and future populations.
The economic costs are substantial and continuing to grow. Water utilities across the United States face billions of dollars in treatment costs to remove PFAS from drinking water supplies. The American Water Works Association estimated that implementing EPA’s PFAS drinking water standards could cost approximately $3.8 billion annually in capital and operational expenses. These costs represent quantifiable economic harm flowing directly from PFAS contamination.
Animal toxicology studies provide biological plausibility for human health effects through consistent demonstration of target organs and mechanisms. The liver, kidney, immune system, and developmental effects observed in laboratory animals occur at exposure levels that overlap with or exceed those found in highly exposed human populations. While interspecies extrapolation requires caution, the consistency of effects across multiple animal species strengthens the biological basis for concluding that PFAS can cause similar effects in humans.
Major scientific and medical organizations have issued formal position statements as evidence regarding health effects has expanded. The Interstate Technology Regulatory Council concluded that PFAS exposure associates with adverse health effects in humans. The American Medical Association has called for regulation of PFAS as a class based on evidence of harm. These institutional positions reflect a broad scientific view that certain PFAS exposures can cause harm, with ongoing debate focused on which effects occur at specific exposure levels.